Members of the UNITE4TB Consortium at the 2023 Annual Meeting
UNITE4TB project coordinator, Martin Boeree (Radboudumc), opens the 2023 Annual Meeting
Members of the UNITE4TB Scientific Advisory Board
Mario Raviglione presented the results of the stakeholder analysis work conducted by his team at the University of Milan
UNITE4TB 2023 Annual Meeting: Day 2, 25 April
Day 2 of the meeting started with a status update on the Phase 2B/C clinical trials. Pictured here is Wandini Lutchmun of project partner, LMU University Hospital Munich
Speakers in a break-out session on the topic of Community Involvement. From left to right: Kristian van Kalmthout (KNCV), Blessina Kumar (UNITE4TB CAG member from the Global Coalition of TB advocates ), and Hanif Esmail (University College London)
The four break-out sessions provided an opportunity for in-depth discussion
Posters on display at the UNITE4TB Annual Meeting
Members of the UNITE4TB Young Investigators Group present their work
Martin Boeree, UNITE4TB project coordinator, presents a certificate to one of the poster prize recipients
Radboudumc hosts, Esther Del Sole (event organizer) and Martin Boeree (UNITE4TB project coordinator)
UNITE4TB Symposium, 26 April 2023
Dean of Radboudumc, Prof. Dr. Jan Smit, opened the Symposium panel discussion
Matteo Zignol of the World Health Organization (R) chairs a session on new ways to design clinical trials with Gerry Davies (University of Liverpool) and Patrick Phillips (University of California: San Francisco)
Kristian van Kalmthout from project partner KNCV led a workshop on Digital Adherence Technology
Participants of the Machine Learning & Artificial Intelligence workshop
Teck Chuan Voo from the National University of Singapore gave a presentation on informed consent in clinical trials during a session on data sharing within UNITE4TB
Participants of the round table discussion on access and pricing of new TB drugs. L-R: Christoph Lange (Research Center Borstel), Matteo Zignol (WHO), Cherise Scott (UNITAID), Brenda Waning (Global Drug Facility) & Mel Spigelman (TB Alliance)
The final session of the Symposium addressed the importance of cross-consortia collaboration. L-R: Andy Vernon (NIH), Charles Wells (Bill & Melinda Gates Medical Research Institute), Norbert Heinrich (LMU), and Simon Tiberi (GSK)
